DexCom Inc (DXCM) stock
DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3033% below fair value
$79.32−0.87 (-1.08%)
Close on Nov 20, 2026Market cap $29.58BP/E 31.2Yield –
DexCom free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
DexCom's free cash flow for the twelve months ending Sep 30, 2026 was $1.10B, up 3.4% year over year. For fiscal 2025 it was $1.08B, up 70.8% from the year before. Over ten years it grew 52.6% a year on average. The highest annual figure on record is $1.08B in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.08B | +70.8% |
| FY2024 | Dec 31, 2024 | $630.70M | +23.2% |
| FY2023 | Dec 31, 2023 | $511.90M | +68.0% |
| FY2022 | Dec 31, 2022 | $304.70M | +471.7% |
| FY2021 | Dec 31, 2021 | $53.30M | -80.7% |
| FY2020 | Dec 31, 2020 | $276.60M | +105.7% |
| FY2019 | Dec 31, 2019 | $134.50M | +139.8% |
| FY2018 | Dec 31, 2018 | $56.10M | +115.8% |
| FY2017 | Dec 31, 2017 | $26.00M | +5100.0% |
| FY2016 | Dec 31, 2016 | $500.00K | -96.8% |
| FY2015 | Dec 31, 2015 | $15.70M | +112.2% |
| FY2014 | Dec 31, 2014 | $7.40M | – |
| FY2013 | Dec 31, 2013 | -$5.50M | – |
| FY2012 | Dec 31, 2012 | -$42.60M | – |
| FY2011 | Dec 31, 2011 | -$38.10M | – |
| FY2010 | Dec 31, 2010 | -$49.60M | – |
| FY2009 | Dec 31, 2009 | -$42.38M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $272.70M | -52.9% |
| Q2 FY2026 | Jun 30, 2026 | $184.50M | -11.7% |
| Q1 FY2026 | Mar 31, 2026 | $449.00M | +363.8% |
| Q4 FY2025 | Dec 31, 2025 | $192.10M | +8.7% |
| Q3 FY2025 | Sep 30, 2025 | $579.40M | +556.2% |
| Q2 FY2025 | Jun 30, 2025 | $208.90M | -2.1% |
| Q1 FY2025 | Mar 31, 2025 | $96.80M | -36.4% |
| Q4 FY2024 | Dec 31, 2024 | $176.80M | +118.0% |
| Q3 FY2024 | Sep 30, 2024 | $88.30M | -59.6% |
| Q2 FY2024 | Jun 30, 2024 | $213.30M | +62.5% |
| Q1 FY2024 | Mar 31, 2024 | $152.30M | +88.7% |
| Q4 FY2023 | Dec 31, 2023 | $81.10M | +17.5% |
| Q3 FY2023 | Sep 30, 2023 | $218.80M | +18.3% |
| Q2 FY2023 | Jun 30, 2023 | $131.30M | +61.5% |
| Q1 FY2023 | Mar 31, 2023 | $80.70M | – |
| Q4 FY2022 | Dec 31, 2022 | $69.00M | +169.5% |
| Q3 FY2022 | Sep 30, 2022 | $185.00M | +32.9% |
| Q2 FY2022 | Jun 30, 2022 | $81.30M | – |
| Q1 FY2022 | Mar 31, 2022 | -$30.60M | – |
| Q4 FY2021 | Dec 31, 2021 | $25.60M | -77.1% |
| Q3 FY2021 | Sep 30, 2021 | $139.20M | +38.9% |
| Q2 FY2021 | Jun 30, 2021 | -$39.60M | -141.3% |
| Q1 FY2021 | Mar 31, 2021 | -$71.90M | – |
| Q4 FY2020 | Dec 31, 2020 | $111.80M | +12.2% |
| Q3 FY2020 | Sep 30, 2020 | $100.20M | +123.7% |
| Q2 FY2020 | Jun 30, 2020 | $95.90M | +444.9% |
| Q1 FY2020 | Mar 31, 2020 | -$31.30M | – |
| Q4 FY2019 | Dec 31, 2019 | $99.60M | +522.5% |
| Q3 FY2019 | Sep 30, 2019 | $44.80M | +35.8% |
| Q2 FY2019 | Jun 30, 2019 | $17.60M | -43.4% |
| Q1 FY2019 | Mar 31, 2019 | -$27.50M | – |
| Q4 FY2018 | Dec 31, 2018 | $16.00M | -32.2% |
| Q3 FY2018 | Sep 30, 2018 | $33.00M | +45.4% |
| Q2 FY2018 | Jun 30, 2018 | $31.10M | +1252.2% |
| Q1 FY2018 | Mar 31, 2018 | -$24.00M | – |
| Q4 FY2017 | Dec 31, 2017 | $23.60M | – |
| Q3 FY2017 | Sep 30, 2017 | $22.70M | – |
| Q2 FY2017 | Jun 30, 2017 | $2.30M | – |
| Q1 FY2017 | Mar 31, 2017 | -$22.60M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.30M | – |
See a number that looks wrong?